{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&q=MDS+AML", "query": { "q": "MDS AML", "condition": "Myelodysplastic Syndromes" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 1288, "total_pages": 129, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelodysplastic+Syndromes&q=MDS+AML&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-10-16T18:14:26.153Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01273766", "title": "Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Adult Grade III Lymphomatoid Granulomatosis", "Adult Langerhans Cell Histiocytosis", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Contiguous Stage II Adult Burkitt Lymphoma", "Contiguous Stage II Adult Diffuse Large Cell Lymphoma", "Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Contiguous Stage II Adult Lymphoblastic Lymphoma", "Contiguous Stage II Grade 1 Follicular Lymphoma", "Contiguous Stage II Grade 2 Follicular Lymphoma", "Contiguous Stage II Grade 3 Follicular Lymphoma", "Contiguous Stage II Mantle Cell Lymphoma", "Contiguous Stage II Marginal Zone Lymphoma", "Contiguous Stage II Small Lymphocytic Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Mast Cell Leukemia", "Myelodysplastic Syndrome With Isolated Del(5q)", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Myeloid/NK-cell Acute Leukemia", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Anemia", "Refractory Multiple Myeloma", "Secondary Acute Myeloid Leukemia", "Secondary Myelofibrosis", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage I Adult Burkitt Lymphoma", "Stage I Adult Diffuse Large Cell Lymphoma", "Stage I Adult Diffuse Mixed Cell Lymphoma", "Stage I Adult Diffuse Small Cleaved Cell Lymphoma", "Stage I Adult Hodgkin Lymphoma", "Stage I Adult Immunoblastic Large Cell Lymphoma", "Stage I Adult Lymphoblastic Lymphoma", "Stage I Adult T-cell Leukemia/Lymphoma", "Stage I Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage I Grade 1 Follicular Lymphoma", "Stage I Grade 2 Follicular Lymphoma", "Stage I Grade 3 Follicular Lymphoma", "Stage I Mantle Cell Lymphoma", "Stage I Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage I Mycosis Fungoides/Sezary Syndrome", "Stage I Small Lymphocytic Lymphoma", "Stage II Adult Hodgkin Lymphoma", "Stage II Adult T-cell Leukemia/Lymphoma", "Stage II Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage II Multiple Myeloma", "Stage II Mycosis Fungoides/Sezary Syndrome", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Adult T-cell Leukemia/Lymphoma", "Stage III Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Mycosis Fungoides/Sezary Syndrome", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "Testicular Lymphoma", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Waldenstrom Macroglobulinemia" ], "interventions": [ { "name": "deferasirox", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "enzyme-linked immunosorbent assay", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2011-01", "completion_date": "2014-12", "has_results": true, "last_update_posted_date": "2018-09-07", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01273766" }, { "nct_id": "NCT00136422", "title": "Study of Vaccination With Autologous Acute Myeloblastic Leukemia Cells in Patients With Advanced Myelodysplasia or Acute Myelogenous Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myelogenous Leukemia", "Myelodysplasia" ], "interventions": [ { "name": "autologous tumor cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2000-01", "completion_date": "2006-03", "has_results": false, "last_update_posted_date": "2011-03-10", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00136422" }, { "nct_id": "NCT01660607", "title": "Phase 1-2 MAHCT w/ TCell Depleted Graft w/ Simultaneous Infusion Conventional and Regulatory T Cell", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Myeloid Leukemia, Chronic", "Acute Myelogenous Leukemia", "Myelodysplastic Syndromes (MDS)", "Lymphoma, Non-Hodgkin", "Acute Lymphoblastic Leukemia (ALL)", "Myeloproliferative Syndrome", "Acute Myeloid Leukemia", "Acute Leukemia", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "CD34+ Hematopoietic Progenitor Cells (HSPC)", "type": "BIOLOGICAL" }, { "name": "Regulatory T-Cells (Treg)", "type": "BIOLOGICAL" }, { "name": "Conventional T-Cells (Tcon)", "type": "BIOLOGICAL" }, { "name": "Myeloablative Conditioning Regimen", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "Stanford University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": "73 Years", "sex": "ALL", "summary": "13 Years to 73 Years" }, "enrollment_count": 68, "start_date": "2012-02-09", "completion_date": "2023-12-20", "has_results": true, "last_update_posted_date": "2025-08-19", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Palo Alto, California", "locations": [ { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01660607" }, { "nct_id": "NCT00700011", "title": "Clofarabine for Myelodysplastic Syndrome (MDS) Patients Who Failed Vidaza Treatment (tx)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myelodysplastic Syndromes" ], "interventions": [ { "name": "Clofarabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Texas Oncology Cancer Center", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 10, "start_date": "2008-03", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2013-03-15", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Amarillo, Texas", "locations": [ { "city": "Amarillo", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00700011" }, { "nct_id": "NCT01085656", "title": "A Phase I Clinical Trial of OXi4503 for Relapsed and Refractory AML and MDS", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia, Myelogenous, Acute", "Myelodysplastic Syndromes" ], "interventions": [ { "name": "OXi4503", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2011-02", "completion_date": "2016-01", "has_results": false, "last_update_posted_date": "2017-08-08", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Gainesville, Florida", "locations": [ { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01085656" }, { "nct_id": "NCT06839456", "title": "Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infections Post TCRab/CD19 Depleted HSCT", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Leukemia", "High Risk Acute Lymphoblastic Leukemia", "High Risk Acute Myeloid Leukemia", "Relapse Leukemia", "MDS (Myelodysplastic Syndrome)", "Relapsed Non-Hodgkin Lymphoma", "Acquired Aplastic Anemia", "Inherited BMF Syndrome", "Immunodeficiency", "Primary Immune Regulatory Disorder", "Hemoglobinopathies", "Bone Marrow Failure", "Inborn Errors of Metabolism", "HLH" ], "interventions": [ { "name": "Phase 1 Dose Level 1", "type": "DEVICE" }, { "name": "Phase 1 Dose Level 2", "type": "DEVICE" }, { "name": "Phase 1 Dose Level 3", "type": "DEVICE" }, { "name": "Phase 2 Maximum Tolerated Dose determined in Phase 1", "type": "DEVICE" }, { "name": "Phase 2 Established Dose from prior study, NCT03810196", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Children's Hospital of Philadelphia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Month", "maximum_age": "25 Years", "sex": "ALL", "summary": "1 Month to 25 Years" }, "enrollment_count": 100, "start_date": "2025-03-21", "completion_date": "2032-03", "has_results": false, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT06839456" }, { "nct_id": "NCT00691015", "title": "Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms" ], "interventions": [ { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "carmustine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "total body irradiation (TBI)", "type": "RADIATION" }, { "name": "anti-thymocyte globulin IV", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 48, "start_date": "2008-05", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2017-06-28", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00691015" }, { "nct_id": "NCT02458235", "title": "Donor Lymphocyte Infusion With Azacitidine to Prevent Hematologic Malignancy Relapse After Stem Cell Transplantation", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphoid Leukemia", "Juvenile Myelomonocytic Leukemia", "Myelodysplastic Syndrome" ], "interventions": [ { "name": "azacitidine", "type": "DRUG" }, { "name": "donor lymphocyte infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "29 Years", "sex": "ALL", "summary": "Up to 29 Years" }, "enrollment_count": 17, "start_date": "2015-06-02", "completion_date": "2019-03-15", "has_results": true, "last_update_posted_date": "2020-10-12", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "San Francisco, California", "locations": [ { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02458235" }, { "nct_id": "NCT02200380", "title": "A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "For Donors", "Related Donors Giving Peripheral Blood Stem Cells (PBSC) to a Sibling", "For Recipients", "Acute Myelogenous Leukemia (AML)", "Acute Lymphoblastic Leukemia (ALL)", "Myelodysplastic Syndrome (MDS)", "Chronic Myelogenous Leukemia (CML)", "Non-Hodgkins Lymphoma (NHL)", "Hodgkins Disease (HD)", "Chronic Lymphocytic Leukemia (CLL)" ], "interventions": [ { "name": "CDX-301", "type": "DRUG" }, { "name": "CDX-301 and plerixafor", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celldex Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 36, "start_date": "2014-07", "completion_date": "2016-04-13", "has_results": false, "last_update_posted_date": "2017-04-07", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 8, "location_summary": "Los Angeles, California • Atlanta, Georgia • Indianapolis, Indiana + 5 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02200380" }, { "nct_id": "NCT00003868", "title": "Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "allogeneic bone marrow transplantation", "type": "PROCEDURE" }, { "name": "peripheral blood stem cell transplantation", "type": "PROCEDURE" }, { "name": "iodine I 131 monoclonal antibody BC8", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "2 Years to 55 Years" }, "enrollment_count": 40, "start_date": "1999-02", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2010-08-24", "last_synced_at": "2026-10-16T18:14:26.153Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003868" } ] }